Samsung Bioepis headquarters in Incheon / Courtesy of Samsung Bioepis
Samsung Bioepis is moving to deepen its global research footprint, signing a partnership with a major Chinese biotech platform to scout and develop next-generation therapies.
The biopharmaceutical company that develops, manufactures and commercializes high-quality biosimilars — lower-cost, clinically proven alternatives to expensive biologic medicines — said Wednesday it signed a memorandum of understanding with ATLATL Innovation Center, a biotech incubation platform, to expand its open innovation strategy and collaborate with emerging biotech firms.
Under the agreement, Samsung Bioepis will identify promising startups and support their early-stage growth by providing access to ATLATL’s research facilities and infrastructure. The partnership marks the company’s first collaboration with an overseas open innovation institution.
ATLATL Innovation Center operates shared laboratories, office space and contract research organization services across key biotech clusters, including Beijing, Shanghai, Singapore and Australia. The platform connects venture companies with global partners to accelerate technology development and commercialization.
Samsung Bioepis said the initiative is aimed at securing advanced biotechnologies across a range of modalities, reflecting a broader push to strengthen its pipeline through external collaboration.
The Korean company said global cooperation has become increasingly critical in driving innovation in the biopharmaceutical sector, where access to cutting-edge infrastructure and expertise can shape the pace of discovery.
Samsung Bioepis said the partnership will help accelerate the discovery and development of new technologies. Seo said the collaboration would allow Samsung Bioepis to leverage advanced infrastructure and specialized capabilities to identify future growth opportunities.
It plans to expand its global open innovation efforts, using partnerships like this to identify high-potential technologies at an early stage and integrate them into its research and development strategy.
This article was published with the assistance of generative AI and edited by The Korea Times.
Source: Korea Times News
